Evidence map›Paper›PMID 40060818›Full record

ArticleACS omega2025

Nanostructured Lipid Carrier for Intracellular Delivery of a Bis(pyridine-2-carboxamidine) DNA Minor Groove Binder Active against

J Jonathan Nué-Martinez, Marta Leo-Barriga, Fernando Herranz, Zisis Koutsogiannis, Paul W Denny, Godwin U Ebiloma, Christophe Dardonville, Ana González-Paredes

Abstract read
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

J Jonathan Nué-MartinezInstituto de Química Médica, IQM-CSIC, Juan de la Cierva 3, E-28006 Madrid, Spain.ORCID https://orcid.org/0000-0001-6483-6892
Marta Leo-BarrigaInstituto de Química Médica, IQM-CSIC, Juan de la Cierva 3, E-28006 Madrid, Spain.ORCID https://orcid.org/0000-0003-4853-5250
Fernando HerranzInstituto de Química Médica, IQM-CSIC, Juan de la Cierva 3, E-28006 Madrid, Spain.ORCID https://orcid.org/0000-0002-3743-0050
Zisis KoutsogiannisDepartment of Biosciences, Durham University, Durham DH1 3LE, U.K.
Paul W DennyDepartment of Biosciences, Durham University, Durham DH1 3LE, U.K.ORCID https://orcid.org/0000-0002-5051-1613
Godwin U EbilomaSchool of Science, Engineering & Environment, University of Salford, Manchester M5 4WT, U.K.ORCID https://orcid.org/0000-0003-4072-9800
Christophe DardonvilleInstituto de Química Médica, IQM-CSIC, Juan de la Cierva 3, E-28006 Madrid, Spain.ORCID https://orcid.org/0000-0001-5395-1932
Ana González-ParedesInstituto de Química Médica, IQM-CSIC, Juan de la Cierva 3, E-28006 Madrid, Spain.ORCID https://orcid.org/0000-0002-3504-0841

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Two types of nanostructured lipid carrier (NLC) formulations of the antileishmanial DNA minor groove binding compound 4-(picolinimidamido)-

Identifiers

PMID40060818
PMCPMC11886747

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.